Children’s Hospital of Philadelphia (CHOP) has received the $1 million Accelerating Hope Award from Children’s Cancer Research Fund (CCRF) to launch an early-phase clinical trial for diffuse midline glioma (DMG), a deadly childhood brain tumor, CHOP announced on November 18, 2026. The three-year grant will fund a trial testing a new form of CAR T-cell therapy made with mRNA technology.
“CCRF has been an ongoing supporter of CHOP, and it is a tremendous honor to have their trust and support as we pursue this exciting new approach to treating DMG,” said Jessica B. Foster, MD, an attending physician at CHOP’s Cancer Center and the trial’s principal investigator.
A New Approach to an Aggressive Tumor
DMG mainly affects young children and young adults. Its location makes it impossible to remove surgically, it resists conventional treatments, and it is typically fatal about a year after diagnosis, according to CHOP.
CAR T-cell therapy reprograms a patient’s own immune cells to attack cancer. The version Dr. Foster’s team will test uses mRNA technology, which CHOP says is designed to make the treatment quicker, safer, and less expensive. The approach has shown early promise in laboratory testing. CHOP says the trial will be the first of its kind on the East Coast.
Along with testing safety and efficacy, the team will study how the immune system and tumor interact during treatment. Those findings could help shape immunotherapy for children with other hard-to-treat brain cancers.
“Their generosity means we’re able to bring hope to children and families dealing with devastating brain cancer — and perhaps to those dealing with other forms of hard-to-treat cancer,” Dr. Foster said.
A Long-Running Partnership
CCRF, a Minnesota-based nonprofit, has supported CHOP since 2016, awarding a total of $3.6 million for research in areas including osteosarcoma, high-risk neuroblastoma, and follow-up care for young survivors. This $1 million gift is its largest yet for brain tumor research at CHOP.
“Dr. Foster’s work is fascinating not just because of what it could mean for children and families dealing with DMG, but also because of how it could change the way we diagnose and treat other hard-to-treat cancers,” said Elizabeth C. Allen, Chief Executive Officer of CCRF.
The Accelerating Hope Award supports clinical trials for hard-to-treat pediatric cancers.
About Children’s Hospital of Philadelphia
Founded in 1855 as the nation’s first pediatric hospital, CHOP is a nonprofit, charitable organization with one of the largest pediatric research programs in the country. Its CHOP Care Network includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances across Pennsylvania, New Jersey, and Delaware.
Source: Children’s Hospital of Philadelphia, https://www.prnewswire.com/news-releases/childrens-hospital-of-philadelphia-receives-1-million-childrens-cancer-research-fund-accelerating-hope-award-302942716.html on November 18, 2026. Republished with credit to the original author. Read the original article.
Contact:
Kaitlyn Dvorin
Children’s Hospital of Philadelphia
610-618-0542 (cell)
[email protected]